NCT00646841View on ClinicalTrials.gov

Effects of Doxazosin Gastrointestinal Therapeutic System on Ambulatory Blood Pressure and Cardiovascular Risk Factors in Uncontrolled Hypertensive Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

89

Participants

Timeline

Start Date

February 28, 2003

Primary Completion Date

February 29, 2004

Study Completion Date

February 29, 2004

Conditions
Hypertension
Interventions
DRUG

Doxazosin gastrointestinal therapeutic system (GITS)

4 mg/day, and was titrated, if necessary, to 8 mg/day at Week 3 (Visit 5) or Week 5 (Visit 6).

Trial Locations (7)

17230

Pfizer Investigational Site, Palamós

20052

Pfizer Investigational Site, Monza (Milan)

25123

Pfizer Investigational Site, Brescia

28041

Pfizer Investigational Site, Madrid

35128

Pfizer Investigational Site, Padua

EC1M 6BQ

Pfizer Investigational Site, London

Unknown

Pfizer Investigational Site

All Listed Sponsors
lead

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

INDUSTRY

NCT00646841 - Effects of Doxazosin Gastrointestinal Therapeutic System on Ambulatory Blood Pressure and Cardiovascular Risk Factors in Uncontrolled Hypertensive Patients | Biotech Hunter | Biotech Hunter